Shares of Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) received a consensus “Buy” recommendation from the seven ratings companies that currently cover the company, Marketbeat Ratings reports. One investment analyst gave the stock a hold rating and five gave the company a buy rating. The 1-year average price target among analysts who have reported on the stock in the past year is $12.00.
Several stock analysts have recently weighed in on the stock. Roth Capital reiterated a “buy” rating on Fortress Biotech shares in a Tuesday, March 29 report. TheStreet downgraded shares of Fortress Biotech from a “c-” rating to a “d+” rating in a Monday, February 14 report. StockNews.com upgraded shares of Fortress Biotech from a “sell” rating to a “hold” rating in a Thursday, May 19 report. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $6.00 price target on Fortress Biotech shares in a Friday, May 13 report.
Several large investors have recently changed their positions in FBIO. Renaissance Technologies LLC increased its position in Fortress Biotech shares by 1,005.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,101,300 shares of the biopharmaceutical company valued at $1,498,000 after purchasing an additional 1,001,653 shares last quarter. Acadian Asset Management LLC increased its stake in Fortress Biotech shares by 169.1% in Q1. Acadian Asset Management LLC now owns 424,693 shares of the biopharmaceutical company worth $575,000 after acquiring 266,853 additional shares in the last quarter. Morgan Stanley increased its stake in shares of Fortress Biotech by 768.2% in Q2. Morgan Stanley now owns 266,945 shares of the biopharmaceutical company worth $953,000 after acquiring 236,198 more shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Fortress Biotech in Q1 valued at $277,000. Finally, Wells Fargo & Company MN increased its stake in Fortress Biotech shares by 293.5% in the 4th quarter. Wells Fargo & Company MN now owns 227,638 shares of the biopharmaceutical company worth $569,000 after acquiring an additional 169,790 shares in the last quarter. Hedge funds and other institutional investors hold 30.92% of the company’s shares.
FBIO opened at $0.91 on Friday. Fortress Biotech has a 52 week low of $0.77 and a 52 week high of $4.49. The company has a quick ratio of 3.15, a current ratio of 3.31 and a leverage ratio of 0.46. The company has a market capitalization of $97.40 million, a P/E ratio of -1.05 and a beta of 2.29. The company’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.69.
Fortress Biotech (NASDAQ:FBIO – Get Rating) last released its quarterly results on Thursday, May 12. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.10. Fortress Biotech had a negative net margin of 88.31% and a negative return on equity of 32.56%. The company posted revenue of $23.93 million for the quarter, versus a consensus estimate of $20.06 million. During the same quarter of the previous year, the company achieved EPS of ($0.11). On average, research analysts expect Fortress Biotech to post -0.77 EPS for the current fiscal year.
Fortress Biotech Company Profile (Get a rating)
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of moderate to severe non-nodular acne vulgaris; Targadox for severe acne; Exelderm cream for symptoms of ringworm and jock itch; Ceracade for dry skin; Luxamend for dressing and treating wounds; and Accutane capsules for severe recalcitrant nodular acne.
Get news and reviews for Fortress Biotech Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fortress Biotech and related companies with MarketBeat.com’s free daily email newsletter.